Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Substance Use Disorders Affecting Sleep01:24

Substance Use Disorders Affecting Sleep

Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is Collaborative Care? Reexamining the Principles of Collaborative Care Through Scaling to Complex Populations and Settings.

Journal of general internal medicine·2026
Same author

A latent class analysis of clinical complexity: Secondary analysis of the collaboration leading to addiction treatment and recovery from other stresses (CLARO) randomized trial.

Addiction (Abingdon, England)·2026
Same author

The impact of collaborative care on perceptions of treatment across racial and ethnic groups.

Frontiers in health services·2026
Same author

Reimbursement Potential of Collaborative Care Model (CoCM) Billing Codes for Opioid Use Disorder Co-Occurring with Mental Disorders: Descriptive Estimates from a Pragmatic Trial.

Administration and policy in mental health·2026
Same author

Stimulant use and increased severity of opioid use disorder and mental illness in patients with co-occurring disorders.

Journal of substance use and addiction treatment·2026
Same author

When Billing Codes Fall Short: Unbillable Time in Collaborative Care for Co-occurring Opioid Use and Mental Health Conditions.

Psychiatric services (Washington, D.C.)·2026
Same journal

Call for commentaries on COVID-19.

Journal of substance abuse treatment·2024
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

TOC (update).

Journal of substance abuse treatment·2023
Same journal

A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations.

Journal of substance abuse treatment·2022
Same journal

Factors associated with the adoption of evidence-based innovations by substance use disorder treatment organizations: A study of HIV testing.

Journal of substance abuse treatment·2022
See all related articles

Related Experiment Video

Updated: May 25, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Treating depression and substance use: a randomized controlled trial.

Sarah B Hunter1, Katherine E Watkins, Kimberly A Hepner

  • 1Drug Policy Research Center, RAND, Santa Monica, CA 90407, USA. shunter@rand.org

Journal of Substance Abuse Treatment
|February 4, 2012
PubMed
Summary
This summary is machine-generated.

This pilot study tested group cognitive-behavioral therapy (CBT) for depression and substance use in outpatient settings. While feasible and acceptable, the intervention did not significantly outperform usual care for co-occurring disorders.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Related Experiment Videos

Last Updated: May 25, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Area of Science:

  • Clinical Psychology
  • Psychiatry
  • Public Health

Background:

  • Limited availability of integrated treatments for co-occurring depression and substance use disorders in outpatient settings.
  • Need for "transportable" interventions deliverable by existing substance abuse treatment staff.
  • Outpatient substance abuse treatment centers are critical access points for individuals with dual diagnoses.

Purpose of the Study:

  • To pilot test a group cognitive-behavioral therapy (CBT) intervention for comorbid depression and substance use.
  • To assess the feasibility and acceptability of delivering this integrated treatment by outpatient substance abuse counselors.
  • To evaluate the preliminary effectiveness of the group CBT intervention compared to usual care.

Main Methods:

  • Pilot randomized controlled trial involving 73 outpatient clients.
  • Intervention group received usual care plus group cognitive-behavioral therapy (CBT).
  • Control group received usual care alone; assessments at baseline, 3, and 6 months.

Main Results:

  • The group CBT intervention was found to be acceptable and feasible for delivery by substance abuse treatment staff.
  • Challenges were noted in client recruitment for the pilot study.
  • Both depressive symptoms and substance use showed reductions in the intervention group, but differences were not statistically significant compared to the control group.

Conclusions:

  • The integrated group CBT intervention shows promise for feasibility and acceptability in outpatient substance abuse settings.
  • Further research is needed to optimize treatment strategies for co-occurring depression and substance use disorders.
  • Enhancing the effectiveness of interventions for dual diagnosis in these settings requires continued investigation.